Table 1.
Characteristics of included populations.
| Population | Country | Report | Design | Cancer | Stage | Regimen | Setting | n | NOS |
|---|---|---|---|---|---|---|---|---|---|
| Antonia 2016 T1 | USA | FA | P1b | NSCLC | Locally advanced or metastatic | D10–20 q2w x26 or q4w x13 + T1 q4w x6 > q12w x3 | 1st or later | 56 | 4 |
| Antonia 2016 T10 | USA | FA | P1b | NSCLC | Locally advanced or metastatic | D15 q4w x13 + T10 q4w x6 > q12w x3 | 1st or later | 9 | 4 |
| Antonia 2016 T3 | USA | FA | P1b | NSCLC | Locally advanced or metastatic | D10–20 q2w x26 or q4w x13 + T3 q4w x6 > q12w x3 | 1st or later | 34 | 4 |
| Boilève 2021 | France | FA | P2 RCT | Biliary tract carcinoma | Recurrent or advanced | D1500 + T75 q4w x4 | 2nd or later | 10 | 4 |
| Brohawn 2018 P1b | USA | CA | P1b | Gastric cancer | Recurrent or metastatic | D20 + T1 q4w > D10 q2w | 2nd | 6 | 4 |
| Brohawn 2018 P2 ArmA | USA | CA | P2 RCT | Gastric cancer | Recurrent or metastatic | D20 + T1 q4w > D10 q2w | 2nd | 27 | 4 |
| Brohawn 2018 P2 ArmD | USA | CA | P2 RCT | Gastric cancer | Recurrent or metastatic | D20 + T1 q4w > D10 q2w | 3rd | 25 | 4 |
| Brohawn 2018 P2 ArmE | USA | CA | P2RCT | Gastric cancer | Recurrent or metastatic | D20 + T1 q4w > D10 q2w | 2nd or 3rd | 19 | 4 |
| Calabro 2018 | Italy | FA | Single arm P2 | Mesothelioma | Unresectable | D20 + T1 q4w x4 > D20 q4w x9 | 1st or 2nd | 40 | 5 |
| Capdevila 2020 | Spain | CA | Single arm P2 | Lung carcinoid, G1/2 gastric, G1/2 pancreatic, G3NEN | Advanced | D1500 q4x13 + T75 q4w x4 | 2nd or later | 123 | 4 |
| Chen 2019 | Canada | CA | P2 RCT | Colorectal carcinoma | Metastatic | D1500 + T75 q4w x4 | 2nd or later | 118 | 5 |
| Cho 2018 | USA | CA | P1 | SCLC | Extensive disease | D20 + T1 q4w | 2nd or later | 30 | 4 |
| Edenfield 2021 | USA | FA | Single arm P2 | Rare cancers | Advanced | D1500 q4w x13 + T75 q4w x7 > q12w x2 | 2nd or later | 44 | 4 |
| Ferrarotto 2020 | USA | FA | RCT | Oropharyngeal cancer | Stage 2–4A | D1500 + T75 day 1, 29 | Neoadj | 14 | 5 |
| Ferris 2020 | USA | FA | P3 | HNSCC | Recurrent or metastatic | D20 + T1 q4w > D10 mg q2w | 2nd-5th | 246 | 4 |
| Gao 2019 | USA | CA | Single arm | Bladder cancer | cT2-T4a | D1500 + T75 q4w x2 | Neoadj | 28 | 4 |
| Hotte 2019 | Canada | CA | P2 RCT | Prostate cancer | Metastatic | D1500 + T75 q4w x4 | 2nd or later | 39 | 4 |
| Karakunnel 2016 | USA | CA | P1 | NSCLC | Advanced | D20 + T1 q4w | Unknown | 102 | 4 |
| Kelley 2020 T300 + D | USA | CA | P3 | HCC | Unresectable | D1500 + T300 q4w | After sorafenib | 74 | 5 |
| Kelley 2020 T75 + D | USA | CA | P3 | HCC | Unresectable | D1500 + T75 q4w | After sorafenib | 82 | 4 |
| Kim 2020 | Korea | FA | Single arm P2 | Pulmonary sarcomatoid carcinoma | Recurrent or metastatic | D1500 + T75 q4w(x4) > D750 q2w(x18) | 1st or adj | 18 | 5 |
| Leighl 2021 | Canada | FA | P2 RCT | NSCLC | 4 | D1500 + T75 q4w x4 > D1500 q4w | Mainly chemo-naive | 149 | 5 |
| Nehra 2020 | Canada | FA | P1B | Solid tumor | Advanced, unresectable, recurrent or metastatic | D1500 + T75 q4w x4 | 1st or 2nd | 7’4 | |
| O’Reilly 2019 | USA | FA | P2 RCT | Pancreatic ductal adenocarcinoma | Recurrent or metastatic | D1500 q4w + T75 q4wx4 > D1500 q4w | 2nd | 32 | 4 |
| Ornstein 2020 cohort2 | USA | CA | P1b | RCC | High risk localized RCC (clinical stage T2b-4 and/or N1, M0 disease) | D + T- > D(x1dose), D + T- > D(x1 year), D + T- > D + T(x1dose) then D(x1 year), D1500 mgT75 mg | Neoadj, adj | 6 | 4 |
| Ornstein 2020 cohort2a | USA | CA | P1b | RCC | High risk localized RCC (clinical stage T2b-4 and/or N1, M0 disease) | D + T > D(x1dose), D + T > D(x1 year), D + T > D + T(x1dose) then D(x1 year), D1500 mgT75 mg | Neoadj, adj | 8 | 4 |
| Ornstein 2020 cohort3 | USA | CA | P1b | RCC | High risk localized RCC (clinical stage T2b-4 and/or N1, M0 disease) | D + T > D(x1dose), D + T > D(x1 year), D + T > D + T(x1dose) then D(x1 year), D1500 mgT75 mg | Neoadj, adj | 8 | 4 |
| Planchard 2020 | France | FA | P3 | NSCLC | Stage3B/4 | D20 mg/kg + T1 mg/kg q4w | 3rd or later | 173 | 4 |
| Powles 2020 | UK | FA | P3 | Urothelial carcinoma | Unresectable, locally advanced, metastatic | D1500 + T75 q4w x4 > D1500 m q4w | 1st | 340 | 5 |
| Ribrag 2021 | France | FA | P1b | DLBCL | Relapsed/refractory | D20 + T1 q4w | 2nd–5th | 3 | 4 |
| Rizvi 2020 | USA | FA | P3 | NSCLC | Stage4 | D20 + T1 q4w | 1st | 371 | 5 |
| Rubinstein 2019 | USA | CA | P2 RCT | Endometrial carcinoma, carcinosarcoma | Persistent or recurrent | D1500 + T75 q4wx4 > D1500 q4w | 2nd | 28 | 4 |
| Santa-Maria 2018 | USA | FA | Single arm (pilot) | Breast cancer | Metastatic | D1500 + T45 q4w x4 > D750 q2w 1 year | 2nd or later | 18 | 3 |
| Sarfaty 2021 | USA | FA | Single arm P2 | Non-urothelial carcinoma of the urinary tract | Unresectable or metastatic | D1500 + T75 q4w x4 > D1500 q4w | 1st–3rd | 13 | 4 |
| Seiwert 2016 | USA | CA | P3 | Head and neck cancer | Recurrent or metastatic | D1500 + T75 q4w > D1500 q4w | 1st | 408 | 4 |
| Siu 2019 | Canada | FA | P2 RCT | HNSCC | Recurrent or metastatic | D20 + T1 q4w x4 | After 1 platinum regimen | 133 | 4 |
| Somaiah 2020 | USA | CA | Single arm P2 | Sarcoma | Advanced or metastatic | D1500 + T75 q4w x4 > D1500 q4w | 1st or later | 57 | 4 |
| Song 2021 China Cohort | USA | CA | P2 RCT | HCC | Advanced | D20 + T1 q4w x4 | After sorafenib | 5 | 4 |
| Song 2021 T1 | USA | CA | P2 RCT | HCC | Advanced | D20 + T1 q4w x4 | After sorafenib | 40 | 4 |
| Song 2021 T300 | USA | CA | P2 RCT | HCC | Advanced | D1500 q4w + T300 x1 | After sorafenib | 74 | 4 |
| Song 2021 T75 | USA | CA | P2 RCT | HCC | Advanced | D1500 q4w + T75 q4w x4 | After sorafenib | 82 | 4 |
Adj, adjuvant therapy; CA, conference abstract; D10, durvalumab 10 mg/kg; D15, durvalumab 15 mg/kg; D1500, durvalumab 1500 mg/body; D20, durvalumab 20 mg/kg; FA, full article; HCC, hepatocellular carcinoma; HNSCC, head and neck squamous cell carcinoma; 1L, first line; n, number of patients; NeoAdj, neo-adjuvant therapy; NOS, score of the Newcastle-Ottawa quality assessment scale for cohort studies wherein higher score means better quality; NS, not specified; NSCLC, non-small cell lung cancer; P1–4, phase 1–4; q2–6w, every 2–6 weeks; RCC, renal cell carcinoma; RCT, randomized controlled trial; T1, tremelimumab 1 mg/kg; T3, tremelimumab 3 mg/kg; T300, tremelimumab 300 mg/body; T45, tremelimumab 45 mg/body; T75, tremelimumab 75 mg/body; x1–26, administrated total 1–26 times; >, then.